Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Optimal duration of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) is debated.
• Current guidelines recommend 6-12 months of DAPT, balancing ischemic event reduction against bleeding risks.
• The DAPT score aids in identifying patients for prolonged therapy, but recent trials challenge longer durations.

Purpose of the Study:

• To review and compare studies on DAPT duration after PCI.
• To analyze evidence supporting shorter DAPT durations and long-term single antiplatelet therapy.
• To evaluate the shift from aspirin to P2Y12 inhibitors post-short-term DAPT.

Main Methods:

• Review of randomized controlled trials and existing literature on DAPT duration.
• Comparative analysis of short-term (1-3 months) versus long-term DAPT regimens.
• Examination of bleeding and ischemic event rates associated with different DAPT strategies.

Main Results:

• Recent trials indicate that shortening DAPT to 1-3 months significantly reduces bleeding events.
• These shorter durations do not substantially increase the risk of ischemic events.
• Replacing aspirin with P2Y12 inhibitors after short-term DAPT is a viable strategy suggested by recent studies.

Conclusions:

• Shorter DAPT durations (1-3 months) are effective and safer, reducing bleeding complications post-PCI.
• Long-term therapy with a single P2Y12 inhibitor may be a preferred alternative to aspirin for sustained antiplatelet effect.
• Evidence supports a paradigm shift towards de-escalating DAPT to shorter durations and single-agent therapy.